FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC

The FDA has granted accelerated approval to zongertinib (Hernexeos) for the treatment of adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC).¹ This indication specifically targets patients whose tumors harbor HER2 tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

This approval expands the indication of zongertinib. In August 2025, the FDA granted accelerated approval to the agent in patients who had received prior systemic therapy.²

The regulatory decision addresses a critical unmet need for patients with HER2-mutant NSCLC, a molecular subtype that has historically lacked diverse targeted therapeutic options. Zongertinib is a tyrosine kinase inhibitor (TKI) designed to selectively target the HER2 protein, which drives oncogenic signaling in this specific patient population.

Clinical Efficacy Data

The approval was supported by data from the Beamion LUNG-1 trial (NCT04886804), an open-label, multicenter, multi-cohort study. The primary efficacy analysis focused on a cohort of 72 patients with unresectable or metastatic nonsquamous NSCLC harboring HER2 TKD mutations. Notably, these patients had not previously received systemic therapy for their advanced disease.

The major efficacy outcomes were objective response rate (ORR) and duration of response (DOR), as assessed by a blinded independent central review using RECIST v1.1 criteria. The trial demonstrated an ORR of 76% (95% CI, 65%-85%). Among the responders, the durability of the treatment effect was significant: 64% maintained a response for at least 6 months, and 44% maintained a response for 12 months or longer.

Zongertinib also stands out due to its efficacy signals in brain metastases. In an interview with Targeted Oncology, Gerrina Ruiter, MD, PhD, Netherlands Cancer Institute, said, “I think the fact that zongertinib works in the brain is the major finding, because we did not know that, and we do not have any HER2 TKI so far that has demonstrated [an] effect in the brain. So, this is really important to show—that this drug not [only] has a high systemic response rate but also induces responses in the brain.” Ruiter is an investigator on the Beamion LUNG-1 trial.

Safety Profile and Adverse Events

The safety evaluation of zongertinib revealed several key areas of clinical concern. The prescribing information includes warnings and precautions for hepatotoxicity, left ventricular dysfunction, and interstitial lung disease (ILD) or pneumonitis. Clinicians are advised to monitor liver function tests and cardiac ejection fraction regularly during treatment.

Additionally, due to the risk of embryo-fetal toxicity, patients of reproductive potential should be advised of the potential risk to a fetus and use effective contraception. The most common adverse reactions reported in clinical trials included gastrointestinal disturbances, fatigue, and rash, consistent with the profile of other kinase inhibitors in this class.

Dosing and Administration

The recommended dosage for zongertinib is weight-based to optimize therapeutic exposure. For patients weighing less than 90 kg, the recommended dose is 120 mg administered orally once daily. For patients weighing 90 kg or more, the dose is increased to 180 mg once daily.

Zongertinib may be taken with or without food. Treatment should continue until disease progression or the occurrence of unacceptable toxicity.

Regulatory Context

The FDA utilized several expedited programs to facilitate this approval, including the Real-Time Oncology Review (RTOR) and the Assessment Aid. The application was granted breakthrough therapy designation and priority review. Furthermore, the review was conducted under the FDA Commissioner’s National Priority Review Voucher (CNPV) pilot program, which aims to accelerate the availability of drugs that address national health priorities.

As this is an accelerated approval, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

REFERENCES

1. FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer. US FDA. February 26, 2026. Accessed February 26, 2026. https://tinyurl.com/bdsfrx7r

2. FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. News release. US FDA. August 8, 2025. Accessed February 26, 2026. https://tinyurl.com/fbakh64s